AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance

U.S. Markets closed

Allergan plc (AGN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
243.86+0.81 (+0.33%)
At close: 4:01PM EDT
People also watch
BIIBCELGVRXGILDREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close243.05
Open243.09
Bid0.00 x
Ask0.00 x
Day's Range240.56 - 244.15
52 Week Range184.50 - 261.27
Volume1,835,243
Avg. Volume2,926,519
Market Cap81.84B
Beta1.29
PE Ratio (TTM)6.39
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.15%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition
    PR Newswire2 days ago

    Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition

    DUBLIN, April 28, 2017 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced it has successfully completed the acquisition of ZELTIQ® Aesthetics, Inc., a medical technology company behind a proprietary controlled-cooling fat reducing treatment, CoolSculpting®. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting held on April 27, 2017.

  • Allergan Plc breached its 50 day moving average in a Bullish Manner : AGN-US : April 28, 2017
    Capital Cube2 days ago

    Allergan Plc breached its 50 day moving average in a Bullish Manner : AGN-US : April 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Allergan Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • TheStreet.com4 days ago

    Teva Confirms CFO Is Leaving

    Eyal Desheh became the Israel-based drugmaker's CFO in 2008.